"If Kevetrin's soon-to-be FDA human trails eclipse in humans that which it has accomplished in mice, we could be looking at an oncolytic therapeutic that either as a solo or part of a drug cocktail may be able to approach the revenue that Lipitor once commanded.
Beth Israel and Pfizer will be able to watch Kevetrin through the dual lenses of both the Pfizer straddle clinicals, as well as the FDA stage 1 at Dana Farber. Remember, Pfizer is the 180 billion cap company with a 15 billion dollar checkbook. A buyout or joint venture twice the size of Celgene's $925 million payment for Avail is pocket change for Pfizer. During or very shortly after Kevetrin's safety profile is established, data may very well be generated that would indicate that Kevetrin's therapeutic platform could have much broader and more significant oncolytic ability than Avail's AVL-292, which is focused on hemoglobic cancers. If indeed that's the case, approximately 16 to 18 months from the initiation of FDA stage 1, Kevetrin might be shared with or owned by a large multinational pharmaceutical company. A point to consider is that the first CEO of Cellceutix was George Evans was former Chief Counsel at Pfizer."
News 
Market Data 
Discover 
AI
